Regulus Therapeutics (RGLS) Misses Q3 EPS by 2c

Regulus Therapeutics (NASDAQ: RGLS) reported Q3 EPS of ($0.18), $0.02 worse than the analyst estimate of ($0.16).

As of September 30, 2017, Regulus had cash, cash equivalents and short-term investments of $71.4 million.

For earnings history and earnings-related data on Regulus Therapeutics (RGLS) click here.

You May Also Be Interested In

• Freightos Limited (CRGO) Tops Q2 EPS by 3c ; Offers Guidance
• BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
• Is Treasury selloff a major issue for stock market bulls?